Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735 ... Premium journey today. Viking Therapeutics (VKTX) Company Description: Viking ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Viking is pursuing VK2809, an experimental treatment for metabolic dysfunction-associated steatohepatitis (MASH), outside VK2735. A Phase 2b VOYAGE study showed that VK2809 dramatically lowers ...

It looks like VK2735 from Viking could compete fiercely with Eli Lilly's tirzepatide. Unfortunately, it's so far behind that it could be somewhat obsolete by the time Viking Therapeutics has a ...